Galectin Therapeutics Company Profile (NASDAQ:GALT)

About Galectin Therapeutics (NASDAQ:GALT)

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:GALT
  • CUSIP: N/A
  • Web: www.galectintherapeutics.com
Capitalization:
  • Market Cap: $63.44 million
  • Outstanding Shares: 34,670,000
Average Prices:
  • 50 Day Moving Avg: $2.16
  • 200 Day Moving Avg: $2.24
  • 52 Week Range: $0.49 - $3.68
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.02 per share
  • Price / Book: 92.00
Profitability:
  • EBIDTA: ($20,480,000.00)
  • Return on Equity: -1,747.01%
  • Return on Assets: -134.48%
Debt:
  • Current Ratio: 2.66%
  • Quick Ratio: 3.21%
Misc:
  • Average Volume: 171,044 shs.
  • Beta: 2.53
  • Short Ratio: 9.6
 
Frequently Asked Questions for Galectin Therapeutics (NASDAQ:GALT)

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its quarterly earnings results on Monday, August, 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same period in the prior year, the firm posted ($0.20) earnings per share. View Galectin Therapeutics' Earnings History.

When will Galectin Therapeutics make its next earnings announcement?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Galectin Therapeutics.

Where is Galectin Therapeutics' stock going? Where will Galectin Therapeutics' stock price be in 2017?

3 equities research analysts have issued 12 month price objectives for Galectin Therapeutics' shares. Their forecasts range from $0.75 to $3.50. On average, they anticipate Galectin Therapeutics' stock price to reach $2.08 in the next year. View Analyst Ratings for Galectin Therapeutics.

Who are some of Galectin Therapeutics' key competitors?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the folowing people:

  • Marc Rubin M.D., Chairman of the Board
  • Peter G. Traber M.D., President, Chief Executive Officer, Chief Medical Officer, Director
  • Jack W. Callicutt, Chief Financial Officer
  • Harold H. Shlevin M.D., Ph.D., Chief Operating Officer, Secretary
  • Eliezer Zomer Ph.D., Executive Vice President - Manufacturing and Product Development
  • J. Rex Horton, Executive Director - Regulatory Affairs and Quality Assurance
  • James C. Czirr, Director
  • Gilbert F. Amelio Ph.D., Independent Director
  • Kevin D. Freeman, Independent Director
  • Arthur R. Greenberg, Independent Director

Who owns Galectin Therapeutics stock?

Galectin Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.51%), D.A. Davidson & CO. (2.13%), Advisor Group Inc. (1.40%), Benchmark Capital Advisors (0.56%), US Bancorp DE (0.34%) and Virtu KCG Holdings LLC (0.31%). Company insiders that own Galectin Therapeutics stock include Arthur Greenberg, James C Czirr and Theodore Daniel Zucconi. View Institutional Ownership Trends for Galectin Therapeutics.

Who sold Galectin Therapeutics stock? Who is selling Galectin Therapeutics stock?

Galectin Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO. and Neuberger Berman Group LLC. View Insider Buying and Selling for Galectin Therapeutics.

Who bought Galectin Therapeutics stock? Who is buying Galectin Therapeutics stock?

Galectin Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Advisor Group Inc., Virtu KCG Holdings LLC and Northern Trust Corp. Company insiders that have bought Galectin Therapeutics stock in the last two years include Arthur Greenberg and Theodore Daniel Zucconi. View Insider Buying and Selling for Galectin Therapeutics.

How do I buy Galectin Therapeutics stock?

Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of Galectin Therapeutics stock can currently be purchased for approximately $1.84.


MarketBeat Community Rating for Galectin Therapeutics (NASDAQ GALT)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  190
MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $2.08 (13.22% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/3/2017FBR & CoReiterated RatingMarket Perform$2.00MediumView Rating Details
3/30/2017HC WainwrightUpgradeNeutral -> Buy$3.50HighView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy -> Sell$3.00 -> $0.75N/AView Rating Details
(Data available from 8/17/2015 forward)

Earnings

Earnings History for Galectin Therapeutics (NASDAQ:GALT)
Earnings by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Earnings History by Quarter for Galectin Therapeutics (NASDAQ GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
8/14/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.17)($0.13)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.22)($0.19)ViewN/AView Earnings Details
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
2017 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.15)($0.13)($0.14)
Q2 20172($0.16)($0.10)($0.13)
Q3 20172($0.12)($0.10)($0.11)
Q4 20172($0.10)($0.09)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Galectin Therapeutics (NASDAQ:GALT)
Insider Ownership Percentage: 40.30%
Institutional Ownership Percentage: 11.00%
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Institutional Ownership by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Insider Trades by Quarter for Galectin Therapeutics (NASDAQ:GALT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/23/2017Theodore Daniel ZucconiDirectorBuy1,000$2.27$2,270.00View SEC Filing  
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Galectin Therapeutics (NASDAQ:GALT)
Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
Source:
DateHeadline
reuters.com logoBRIEF-Galectin Therapeutics Q2 loss per share $0.14
www.reuters.com - August 15 at 12:17 AM
globenewswire.com logoGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - August 14 at 7:14 PM
finance.yahoo.com logoGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
finance.yahoo.com - August 14 at 7:14 PM
americanbankingnews.com logoGalectin Therapeutics Inc. (GALT) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - August 14 at 8:50 AM
americanbankingnews.com logoGalectin Therapeutics Inc (NASDAQ:GALT) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 7 at 7:06 AM
americanbankingnews.com logo Analysts Anticipate Galectin Therapeutics Inc. (NASDAQ:GALT) to Announce -$0.13 EPS
www.americanbankingnews.com - August 5 at 4:16 PM
streetinsider.com logoGalectin Therapeutics (GALT) Granted Patent for Enhancing Immunotherapy in Cancer Treatment
www.streetinsider.com - July 27 at 5:32 AM
streetinsider.com logoGalectin Therapeutics (GALT) Granted Patent for Enhancing Immunotherapy in Cancer Treatment - StreetInsider.com
www.streetinsider.com - July 26 at 12:10 AM
bizjournals.com logoTechnical Reports on Generic Drugs Equities -- pSivida, Tetraphase Pharma, Catalyst Pharma, and Galectin Therapeutics
www.bizjournals.com - July 25 at 7:09 PM
finance.yahoo.com logoPatent for Enhancing Immunotherapy in Cancer Treatment Granted to Galectin Therapeutics
finance.yahoo.com - July 25 at 7:09 PM
americanbankingnews.com logoGalectin Therapeutics Inc. (GALT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 19 at 12:12 AM
americanbankingnews.com logoGalectin Therapeutics (NASDAQ:GALT) & Biohaven Pharmaceutical Holding Co (BHVN) Head-To-Head Comparison
www.americanbankingnews.com - July 18 at 2:45 PM
americanbankingnews.com logo Brokerages Expect Galectin Therapeutics Inc. (GALT) to Post -$0.13 EPS
www.americanbankingnews.com - July 14 at 12:26 PM
globenewswire.com logoGalectin Therapeutics to Present at the Singular Research Summer Conference - GlobeNewswire (press release)
globenewswire.com - July 9 at 2:12 AM
finance.yahoo.com logoGalectin Therapeutics to Present at the Singular Research Summer Conference
finance.yahoo.com - July 8 at 10:57 AM
finance.yahoo.com logoAmmo, Inc. Appoints Two Senior Executives to Board of Directors
finance.yahoo.com - June 29 at 10:26 PM
globenewswire.com logoPatent for Reducing Inflammatory Response Granted to Galectin Therapeutics - GlobeNewswire (press release)
globenewswire.com - June 23 at 3:21 PM
finance.yahoo.com logo[$$] Drug Companies Seek to Raise Awareness of Liver Ailment
finance.yahoo.com - June 23 at 3:21 PM
reuters.com logoBRIEF-Galectin Therapeutics says patent granted for reducing inflammatory response
www.reuters.com - June 22 at 11:21 PM
streetinsider.com logoGalectin Therapeutics (GALT) Receives Patent for Reducing ... - StreetInsider.com
www.streetinsider.com - June 21 at 6:57 PM
finance.yahoo.com logoPatent for Reducing Inflammatory Response Granted to Galectin Therapeutics
finance.yahoo.com - June 21 at 6:57 PM
americanbankingnews.com logoGalectin Therapeutics Inc. (GALT) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - June 20 at 10:26 AM
americanbankingnews.com logoGalectin Therapeutics Inc. (GALT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - June 18 at 8:20 PM
streetinsider.com logoGalectin Therapeutics' (GALT) NASH CX Trial Should Continue, Says Independent Data Safety Monitoring Board
www.streetinsider.com - June 13 at 10:10 PM
streetinsider.com logoGalectin Therapeutics' (GALT) NASH CX Trial Should Continue ... - StreetInsider.com
www.streetinsider.com - June 13 at 5:10 PM
reuters.com logoBRIEF-Galectin Therapeutics updates on completion of Nash Cx trial
www.reuters.com - June 13 at 11:21 AM
finance.yahoo.com logoGalectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
finance.yahoo.com - June 13 at 11:21 AM
prnewswire.com logoGeneric Drugs Stocks on Investors' Radar -- Catalyst Pharma, Lannett, Evoke Pharma, and Galectin Therapeutics - PR Newswire (press release)
www.prnewswire.com - June 7 at 11:06 AM
globenewswire.com logoAutoimmune Disease Patent Granted to Galectin Therapeutics ... - GlobeNewswire (press release)
globenewswire.com - June 6 at 10:46 PM
reuters.com logoBRIEF-Autoimmune disease patent granted to Galectin Therapeutics
www.reuters.com - June 6 at 5:45 PM
finance.yahoo.com logoAutoimmune Disease Patent Granted to Galectin Therapeutics
finance.yahoo.com - June 6 at 5:45 PM
americanbankingnews.com logoGalectin Therapeutics Inc (GALT) Short Interest Down 4.7% in May
www.americanbankingnews.com - June 4 at 9:46 AM
americanbankingnews.com logoGalectin Therapeutics Inc (GALT) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 26 at 10:28 PM
seekingalpha.com logoGalectin Therapeutics: Serendipity In Psoriasis, Strength In NASH - Seeking Alpha
seekingalpha.com - May 24 at 12:04 PM
seekingalpha.com logoGalectin Therapeutics: 1 More Shot To Get It Right?
seekingalpha.com - May 23 at 11:50 AM
reuters.com logoBRIEF-Galectin Therapeutics files for stock offering of up to $100 mln
www.reuters.com - May 19 at 10:10 PM
nasdaq.com logoGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update - Nasdaq
www.nasdaq.com - May 16 at 5:17 PM
americanbankingnews.com logoGalectin Therapeutics Inc (GALT) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 16 at 5:10 PM
globenewswire.com logoGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - May 16 at 11:38 AM
marketwatch.com logo10-Q: GALECTIN THERAPEUTICS INC
www.marketwatch.com - May 15 at 11:24 AM
finance.yahoo.com logoGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 11:24 AM
americanbankingnews.com logoGalectin Therapeutics (GALT) Receiving Positive News Coverage, Report Shows
www.americanbankingnews.com - May 4 at 10:10 AM
finance.yahoo.com logoGalectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
finance.yahoo.com - May 3 at 5:09 PM
americanbankingnews.com logoZacks: Analysts Anticipate Galectin Therapeutics Inc (GALT) to Announce -$0.15 EPS
www.americanbankingnews.com - May 2 at 10:32 AM
finance.yahoo.com logoGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02 - Yahoo Finance
finance.yahoo.com - April 27 at 10:57 PM
americanbankingnews.com logoGalectin Therapeutics (GALT) Getting Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 26 at 6:00 PM
finance.yahoo.com logoGalectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
finance.yahoo.com - April 25 at 11:16 AM
finance.yahoo.com logoWill Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?
finance.yahoo.com - April 24 at 5:06 PM
americanbankingnews.com logoGalectin Therapeutics (GALT) Given Coverage Optimism Score of 0.56
www.americanbankingnews.com - April 23 at 8:02 AM
finance.yahoo.com logoCan Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?
finance.yahoo.com - April 20 at 12:12 PM

Social

Chart

Galectin Therapeutics (GALT) Chart for Thursday, August, 17, 2017

This page was last updated on 8/17/2017 by MarketBeat.com Staff